Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Formulation of Lipid Nanoparticles based Nanogel of Sertaconazole Nitrate and its Evaluation

Author(s): Sarvesh S. Pawar, Punam S. Gadekar, Bhushan R. Rane* and Ashish S. Jain

Volume 14, Issue 1, 2024

Published on: 10 October, 2023

Page: [28 - 40] Pages: 13

DOI: 10.2174/0124681873255919231002044416

Price: $65

Abstract

Background: Sertaconazole nitrate is a topical antifungal drug used to treat interdigital tinea pedis in patients with immunocompetent conditions. The class of imidazole includes the antifungal medication sertaconazole nitrate. It is available in topical formulations for treating skin infections, including athlete's foot. Solid lipid nanoparticles (SLN) are at the cutting edge of nanotechnology, with several potential uses in drug delivery and research. Because of their unique size-dependent features, lipid nanoparticles hold the promise of novel therapies.

Objective: Drug incorporation into nanocarriers creates a new drug delivery prototype that could be employed for drug targeting. The research aims to study the formulation and evaluation of Sertaconazole nitrate solid lipid nanoparticles. The goal behind formulating SLN gel is to provide and maintain therapeutic concentrations of the drug at the target biological site to maximise therapeutic efficacy and minimise side effects.

Methods: Sertaconazole Nitrate Solid Lipid Nanoparticles are prepared by using High Pressure Homogenizer to get nanogel formulation as the final formulation and in vitro drug release using a diffusion apparatus. The prepared SLNs were evaluated in their FTIR studies to determine compatibility between the drug and the excipients; zeta potential indicates the solid lipid nanoparticle was stable, and polydispersity index was used to determine particle size.

Result: The results demonstrate that optimised SLN-based Sertaconazole nitrate gel exhibited the best physicochemical properties, including FTIR studies of the drug, excipients, and optimised formulation demonstrate that all are compatible with each other, particle size is less than 200 nm, zeta potential ranging from 12 to -20 mV, and highest entrapment efficiency is 71.48%. Optimised solid lipid nanoparticles showed good in vitro release and antimicrobial results. The main application of SLN large scale-up is possible, and the drug can be effective with less dose incorporation.

Conclusion: In this research work, the proposed plan of work SLN of Sertaconazole Nitrate was formulated successfully. The preliminary identification tests were performed, such as melting point determination, estimation of λmax by UV-visible spectrophotometry and plot of its calibration curve in solvent and buffer system, and FT-IR investigation to confirm the purity and confirmation of medication. High physical stability and drug loading are advantageous to SLN.

« Previous Next »
Graphical Abstract

[1]
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv Pharm Bull 2015; 5(3): 305-13.
[http://dx.doi.org/10.15171/apb.2015.043] [PMID: 26504751]
[2]
Borges G, Oliveria M. Solid lipid nanoparticles and nanostructured lipid carriers for drug delivery applications. In: Borges GS, Oliveira MS, dos Santos DCM, Ferreira LAM, Carneiro G, Eds Drug Deliv. 2021; pp. (Part II): 1-56.
[http://dx.doi.org/10.2174/9781681088235121010004]
[3]
Santos Maia C, Mehnert W, Schaller M, et al. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002; 10(6): 489-95.
[http://dx.doi.org/10.1080/1061186021000038364] [PMID: 12575739]
[4]
Garud A, Singh D, Garud N. Solid Lipid Nanoparticles (SLN): Method, characterization and applications. Int Curr Pharm J 2012; 1(11): 384-93.
[http://dx.doi.org/10.3329/icpj.v1i11.12065]
[5]
Anderluzzi G, Lou G, Su Y, Perrie Y. Scalable manufacturing processes for solid lipid nanoparticles. Pharm Nanotechnol 2019; 7(6): 444-59.
[http://dx.doi.org/10.2174/2211738507666190925112942] [PMID: 31840610]
[6]
Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3): 165-96.
[http://dx.doi.org/10.1016/S0169-409X(01)00105-3] [PMID: 11311991]
[7]
Shirkhedkar AA, Patil PS. Breakthroughs in transdermal nanostructured lipid carrier drug delivery systems. Int J Pharm Sci Res 2021; 12(3): 1352-66.
[8]
Rajpoot K. Solid lipid nanoparticles: A promising nanomaterial in drug delivery. Curr Pharm Des 2019; 25(37): 3943-59.
[http://dx.doi.org/10.2174/1381612825666190903155321] [PMID: 31481000]
[9]
Sawant GS, Sutar KV, Kanekar AS. Liposome: A novel drug delivery system. Int J Res Rev 2021; 8(4): 252-68.
[http://dx.doi.org/10.52403/ijrr.20210433]
[10]
Mishra H, Chauhan V, Kumar K, Teotia D. A comprehensive review on Liposomes: A novel drug delivery system. J Drug Deliv Ther 2018; 8(6): 400-4.
[http://dx.doi.org/10.22270/jddt.v8i6.2071]
[11]
Agarwal K. Liposome assisted drug delivery-an updated review. Indian J Pharm Sci 2022; 84(4)
[http://dx.doi.org/10.36468/pharmaceutical-sciences.975]
[12]
Chauhan I, Singh L. A comprehensive literature review of lipids used in formulation of lipid nanoparticles. Curr Nanomater 2022; 07: 2405461507666220606164446.
[http://dx.doi.org/10.2174/2405461507666220606164446]
[13]
Vyas SP, Khar RK. Targeted and Controlled Drug Delivery Novel Carrier System. (1st ed.). CBS Publication 2002; pp. 346-79.
[14]
Gannu R, Yamsani MR. Transdermal delivery systems. In: Yamsani MR, Jithan AV, Eds. Advances in Drug Delivery. India: PharmaMed Press 2014; Vol. 2: pp. 1-56.
[15]
Liu M, Wen J, Sharma M. Solid lipid nanoparticles for topical drug delivery: Mechanisms, dosage form perspectives, and translational status. Curr Pharm Des 2020; 26(27): 3203-17.
[http://dx.doi.org/10.2174/1381612826666200526145706] [PMID: 32452322]
[16]
Sinha V, Srivastava S, Goel H, Jindal V. Solid Lipid Nanoparticles (SLN’S) -trends and implications in drug targeting. Int J Adv Pharmaceut Sci 2010; 1(3): 212-38.
[17]
Samundre P, Dangi S, Patidar T, Shende SM. A review on topical gel. Int J Creat Res Thoughts 2020; 8: 3952.
[18]
Sahu SK, Raj R, Raj PM, Alpana R. Topical lipid based drug delivery systems for skin diseases: A review. Curr Drug Ther 2018; 13: 1574885513666181112153213.
[http://dx.doi.org/10.2174/1574885513666181112153213]
[19]
Sertaconazole nitrate. Available from: https://www.trc-canada.com/product-detail/?S278500 (Accessed on 01 July 2021)
[20]
Chaudhari PM, Patil AR. Optimization of itroconazole solid lipid nanoparticles for topical delivery. Nanosci Nanotechnol Asia 2020; 10(4): 381-9.
[http://dx.doi.org/10.2174/2210681208666181112142717]
[21]
Efendieva ZN. Sertaconazole in the treatment of vulvovaginal candidiasis. Med Council 2019; (13): 94-8.
[http://dx.doi.org/10.21518/2079-701X-2019-13-94-98]
[22]
Patil M, Bhagade P, Amale M, Sonawane S, Kshirsagar S. Development of sertaconazole nitrate loaded nanostructured lipid carriers gel using central composite design: In-vitro and ex-vivo evaluation. Nanosci Nanotechnol Asia 2020; 10: 2210681210999200513093420.
[http://dx.doi.org/10.2174/2210681210999200513093420]
[23]
Nugraha MW, Iswandana R, Jufri M. Preparation, characterization, and formulation of solid lipid nanoparticles lotion from mulberry roots (Morus Alba L). Int J Appl Pharmaceut 2020; 182-186: 182-6.
[http://dx.doi.org/10.22159/ijap.2020.v12s1.FF041]
[24]
P.P B. Formulation and evaluation of solid lipid nanoparticles of bifonazole. Int J Sci Res Sci Technol 2020; 105-20.
[http://dx.doi.org/10.32628/IJSRST207522]
[25]
Muralikrishnan R, Devi K. Formulation, evaluation and applications of solid lipid nanoparticles: An overview. Int Res J Pharma 2019; 10(12): 1-12.
[http://dx.doi.org/10.7897/2230-8407.1012322]
[26]
Souto EB, Müller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul 2006; 23(4): 377-88.
[http://dx.doi.org/10.1080/02652040500435295] [PMID: 16854814]
[27]
GANNIMANI VR. GADELA VR. Formulation, optimization and in vitro evaluation of lovastatin drug loaded solid lipid nanoparticles. Int J Pharmaceut Res 2020; 12(4)
[http://dx.doi.org/10.31838/ijpr/2020.12.04.488]
[28]
Kesharwani R, Sachan A, Singh S, Patel D. Formulation and evaluation of Solid Lipid Nanoparticle (SLN) based topical gel of etoricoxib. J Appl Pharm Sci 2016; 124-31.
[http://dx.doi.org/10.7324/JAPS.2016.601017]
[29]
VIJAY K. SHABNAM A. Optimization and evaluation of topical gel containing solid lipid nanoparticles loaded with luliconazole and its anti-fungal activity. Int J Pharmaceut Res J Pharm Res 2020; 12(sp2)
[http://dx.doi.org/10.31838/ijpr/2020.SP2.169]
[30]
Kumar V, Kumar B, Ain S, Ain Q. Optimization and evaluation of topical gel containing solid lipid nanoparticles loaded with luliconazole. Res Gate 2020; 12(2): 2903-4.
[31]
Bhalekar M, Upadhaya P, Madgulkar A. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir. Appl Nanosci 2017; 7(1-2): 47-57.
[http://dx.doi.org/10.1007/s13204-017-0547-1]
[32]
Niyaz BB, Kalyani P, Divakar G. Formulation and evaluation of gel containing fluconazole antifungal agent. Int J Drug Develop Res 2011; 3(4): 109-28.
[33]
Biswajit B, Nabin K. Formulation and evaluation of microemulsion based topical hydrogel containing lornoxicam. J Appl Pharm Sci 2014; 4(12): 077-84.
[http://dx.doi.org/10.7324/JAPS.2014.41214]
[34]
Demirel M, Yazan Y, Müller RH, Kiliç F, Bozan B. Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul 2001; 18(3): 359-71.
[http://dx.doi.org/10.1080/02652040010018119] [PMID: 11308226]
[35]
Gouda R, Baishya H, Qing Z. Application of mathematical models in drug release kinetics of carbidopa and levodopa er tablets. J Dev Drugs 2017; 6(2): 1-8.
[36]
M S, v C. Antifungal drug resistance among candida albicans and non-albicans candida species isolates from a tertiary care centre at allahabad. J Antimicrob Agents 2017; 3(4): 1000150.
[http://dx.doi.org/10.4172/2472-1212.1000150]
[37]
Pandey A, Jagtap JV, Polshettiwar SA, Kuchekar BS. Formulation and evaluation of antibacterial and antifungal activity of herbal gel containing aloe vera, azadirachta indica and lycopersicon esculentum seed extract. RJPT 2011; 4(4): 552-4.
[38]
Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal 2016; 6(2): 71-9.
[http://dx.doi.org/10.1016/j.jpha.2015.11.005] [PMID: 29403965]
[39]
Göppert TM, Müller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J Drug Target 2005; 13(3): 179-87.
[http://dx.doi.org/10.1080/10611860500071292] [PMID: 16036306]
[40]
Yadav P, Rath G, Sharma G, Singh R, Goyal AK. Polysorbate 80 coated solid lipid nanoparticles for the delivery of temozolomide into the brain. Open Pharmacol J 2018; 8(1): 21-8.
[http://dx.doi.org/10.2174/1874143601808010021]
[41]
Heiati H, Tawashi R, Phillips NC. Solid lipid nanoparticles as drug carriers - II. Plasma stability and bio-distribution of solid lipid noparticles containing the lipophilic prodrug 3′-azido-3′- deoxythymidine palmitate in mice. Int J Pharm 1997; 149: 255-65.
[42]
Anderluzzi G, Perrie Y. Microfluidic manufacture of solid lipid nanoparticles: A case study on tristearin-based systems. Drug Deliv Lett 2019; 09: 2210303109666190807104437.
[http://dx.doi.org/10.2174/2210303109666190807104437]
[43]
Reddy CSK, Khan KKA, Nagaraja C. A review on the determination of melting point measurement system. IJAREEIE 2016; 5(2): 975-9.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy